On April 13, 2018 Kitov Pharma (NASDAQ and TASE: KTOV), reported that TyrNovo Ltd., a company majority-owned by Kitov, will present pre-clinical data on TyrNovo’s anti-tumor resistance drug candidate, NT219, in a poster session at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2018, to be held on April 14-18, at the McCormick Place, Chicago, Illinois (Press release, Kitov Pharmaceuticals , APR 13, 2018, View Source [SID1234525304]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The poster highlights recent promising results, further demonstrating NT219’s efficacy in synergy with immuno-oncology therapies. The recent results, achieved using double autologous PDX models, demonstrated that NT219 converted non-responding tumors to responders to pembrolizumab (Keytruda). The models also demonstrated the efficacy of NT219 in enhancing the immunotherapeutic potential of cetuximab (Erbitux).
Details on the poster presentations are as follows:
Session Title: Immune Mechanisms Invoked by Therapies 1
Session Time: 4/16/2018 1:00 PM – 5:00 PM ET
Location: Poster Section 33
Poster Board Number: 2754 / 16
About NT219
NT219 is a small molecule that presents a new concept in cancer therapy by promoting the degradation and inhibiting the phosphorylation of two oncology-related checkpoints, Insulin Receptor Substrates (IRS) 1 and signal transducer and activator of transcription 3 (STAT3), respectively. While targeted anti-cancer drugs inhibit the "ON" signal, NT219 activates the "OFF" switch, extensively blocking major oncogenic pathways. In pre-clinical trials, NT219, in combination with several approved cancer drugs, displayed potent anti-tumor effects and increased survival in various cancers, including sarcoma, melanoma, pancreatic, lung, ovarian, head & neck, prostate and colon cancers, by preventing the tumors from developing drug resistance and reversing resistance after it had been acquired.
About TyrNovo
TyrNovo Ltd., a Kitov Pharma (NASDAQ/TASE: KTOV) company, is a developer of novel small molecules in the oncology therapeutic field. TyrNovo is developing NT219, an oncology product designed to be used in combination with other oncology drugs. NT219 is a small molecule that presents a new concept in cancer therapy. In combination with various approved oncology drugs, NT219 has demonstrated potent anti-tumor effects and increased survival in various cancer models, including sarcoma, melanoma, pancreatic, lung, ovarian, head & neck, prostate and colon cancers. Its mechanism of action is through the prevention of acquired resistance in tumors and by regression of resistant tumors. For more information on TyrNovo please visit View Source